University of North Carolina at Chapel Hill, Department of Family Medicine; Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill, Department of Epidemiology; Chapel Hill, NC, United States.
Vaccine. 2024 Oct 3;42(23):126237. doi: 10.1016/j.vaccine.2024.126237. Epub 2024 Aug 24.
The introduction of vaccines during the COVID-19 pandemic provided an opportunity to slow transmission of SARS-CoV-2, but initial uptake of COVID-19 vaccination was slow. We analyzed data from a randomized clinical trial of the mRNA-1273 vaccine (NCT04811664) to describe the patterns of uptake of COVID-19 vaccines among young adults.
The CoVPN 3006 trial randomized adults ages 18-29 from 44 sites in the United States to receive 1) immediate mRNA-1273 vaccination from the study site, or 2) standard of care, including the option to seek vaccination at any time in the future. Randomization occurred between March and November 2021, and an observational arm of adults who declined vaccination was enrolled beginning June 2021. Among participants in the standard of care (SoC) or Vaccine Declined arms, we estimated demographic, behavioral, and health history correlates of vaccination, and the four-month cumulative incidence of COVID-19 vaccination using inverse probability weighted Kaplan-Meier estimators.
Among 728 SoC and 470 Vaccine Declined participants, 79% and 16% received COVID-19 vaccination, respectively. SoC and Vaccine Declined participants were more likely to seek and receive vaccination if they reported COVID-19 preventive behaviors, including wearing masks, physically distancing, and avoiding large gatherings. We identified strong predictors of vaccination in the Vaccine Declined arm, including attending class in person (adjusted risk ratio [aRR]: 0.47, 95% confidence interval [CI] 0.21, 1.03), having a COVID-19 relevant medical condition (aRR: 1.95, 95% CI: 0.89, 4.26), and avoiding large gatherings (aRR: 2.24, 95% CI: 1.18, 4.25), though low vaccination rates in this arm led to imprecise estimates.
Individuals who initially decline vaccination can be convinced to vaccinate, particularly if they are already practicing other forms of COVID-19 prevention. Continued outreach and education from the scientific community can combat low vaccine confidence.
在 COVID-19 大流行期间引入疫苗为减缓 SARS-CoV-2 的传播提供了机会,但 COVID-19 疫苗的初始接种率较低。我们分析了 mRNA-1273 疫苗的一项随机临床试验(NCT04811664)的数据,以描述年轻人中 COVID-19 疫苗接种的模式。
CoVPN 3006 试验随机选择了来自美国 44 个地点的 18-29 岁成年人,将他们分为两组:1)立即在研究地点接种 mRNA-1273 疫苗,或 2)接受标准护理,包括将来随时接种疫苗的选择。随机分组于 2021 年 3 月至 11 月进行,2021 年 6 月开始招募拒绝接种疫苗的成年人观察臂。在标准护理(SoC)或疫苗拒绝组的参与者中,我们使用逆概率加权 Kaplan-Meier 估计来估计与疫苗接种相关的人口统计学、行为和健康史因素,以及 COVID-19 疫苗接种的四个月累积发生率。
在 728 名 SoC 和 470 名疫苗拒绝参与者中,分别有 79%和 16%接种了 COVID-19 疫苗。如果报告了 COVID-19 预防措施,包括戴口罩、保持身体距离和避免大型聚会,SoC 和疫苗拒绝参与者更有可能寻求并接种疫苗。我们在疫苗拒绝组中确定了疫苗接种的强预测因素,包括亲自上课(调整风险比[aRR]:0.47,95%置信区间[CI]:0.21,1.03)、有 COVID-19 相关医疗状况(aRR:1.95,95%CI:0.89,4.26)和避免大型聚会(aRR:2.24,95%CI:1.18,4.25),尽管该组的疫苗接种率较低导致估计结果不精确。
最初拒绝接种疫苗的人可以被说服接种疫苗,尤其是如果他们已经在采取其他形式的 COVID-19 预防措施。科学界的持续宣传和教育可以消除对疫苗的信心不足。